Fulcrum Therapeutics Inc FULC

$3.69 -0.05 (-1.34%)

Valuation

Market cap
284,141,000
Revenue TTM
$0
Net income TTM
$-74,880,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,487,633
Avg volume
1,366,018
Day's range
$3.68 – $3.74
Shares out
76,382,000
Stochastic %K
71%
Beta
2.82
Analysts
Hold
Price target
$6.40

Price

Company profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also...

Show more

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 651 8851
Website
https://www.fulcrumtx.com
Address
26 Landsdowne Street, Cambridge, United States

Latest news

Stocktwits

Merlintrader Nov 1, 8:22 PM
$FULC closed the week at $3.71 (+0.8% w/w), below the 50-day SMA ($3.76) and below the 200-day ($5.86). RSI14 48.8. 20-day range $3.63-$3.80. FULC Stock Hub: Fulcrum Therapeutics News, Operations and Capital https://www.merlintrader.com/fulcrum-therapeutics-fulc-stock-hub/
0 replies
BKronic5 Oct 1, 4:31 PM
$FULC need an update since they want to make a deal for below everyone’s average cost on this piece of garbage company. Was looking promising on sickle cell then the awful news on 6/2
0 replies
Merlintrader Sep 19, 7:37 PM
Fulcrum Therapeutics ($FULC) Stock Hub Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/fulcrum-therapeutics-fulc-stock-hub/
0 replies
Merlintrader Sep 3, 4:28 PM
@merlintrader Fulcrum Therapeutics (Nasdaq: $FULC) Stock Hub 2026: What Does The Slate Medicines Reverse Merger And A $270 Million Cash Dividend Mean For Shareholders? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/fulcrum-therapeutics-fulc-stock-hub/
0 replies
focafoca99 Sep 2, 3:32 PM
$FULC exposes a securities investigation by Kaplan Fox, urging investors to submit tips and seek compensation.
0 replies
focafoca99 Aug 31, 2:46 PM
$FULC exposes a securities law investigation by Kaplan Fox targeting the company.
0 replies
focafoca99 Aug 24, 6:21 PM
$FULC undergoes a securities-fraud investigation by Kaplan Fox on behalf of investors.
0 replies
Merlintrader Aug 24, 3:25 PM
$FULC Fulcrum Therapeutics Stock Hub 2026: the Slate Medicines reverse merger, a 270 million dollar cash dividend and a 5 per cent stake in a migraine company https://www.merlintrader.com/fulcrum-therapeutics-fulc-stock-hub/
0 replies